# Study of ODX (OsteoDex) in Multiple Myeloma

Source: https://onco.cc/trials/nct06616389/  
OnCo record `nct06616389` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ODX (Osteodex) in multiple myeloma, run by DexTech Medical AB, now recruiting.

## Summary

Study of ODX (OsteoDex) in Multiple Myeloma is a phase 1/2 interventional study registered as NCT06616389 by DexTech Medical AB, with 12 participants planned, started 2023-11-29 and due to reach its primary completion in 2026-01-30. Interventions recorded: ODX (Osteodex).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06616389
- Phase: 1/2
- Setting: A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma
- Sponsor: DexTech Medical AB
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT06616389: https://clinicaltrials.gov/study/NCT06616389

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)

---
JSON: https://onco.cc/api/v1/entities/nct06616389.json